Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
| Autor: | Gissette Reyes-Soffer, Marit Westerterp |
|---|---|
| Přispěvatelé: | Center for Liver, Digestive and Metabolic Diseases (CLDM), Translational Immunology Groningen (TRIGR) |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Apolipoprotein B Inflammation 03 medical and health sciences chemistry.chemical_compound DOUBLE-BLIND 0302 clinical medicine Tocilizumab Internal medicine medicine LP(A) LIPOPROTEIN Animals Humans OXIDIZED PHOSPHOLIPIDS Risk factor Receptor TOCILIZUMAB Pharmacology RISK biology business.industry STAGE RENAL-DISEASE Lipoprotein(a) medicine.disease Atherosclerosis RHEUMATOID-ARTHRITIS 030104 developmental biology Endocrinology chemistry CARDIOVASCULAR-DISEASE INTERLEUKIN-6 RECEPTOR Cardiovascular Diseases 030220 oncology & carcinogenesis Rheumatoid arthritis APOLIPOPROTEIN(A) PHENOTYPES biology.protein medicine.symptom business Lipoprotein |
| Zdroj: | Pharmacological research, 169:105689. ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD |
| ISSN: | 1096-1186 1043-6618 |
| Popis: | Genome wide association, epidemiological, and clinical studies have established high lipoprotein(a) [Lp(a)] as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is an apoB100 containing lipoprotein covalently bound to apolipoprotein(a) [apo(a)], a glycoprotein. Plasma Lp(a) levels are to a large extent determined by genetics. Its link to cardiovascular disease (CVD) may be driven by its pro-inflammatory effects, of which its association with oxidized phospholipids (oxPL) bound to Lp(a) is the most studied. Various inflammatory conditions, such as rheumatoid arthritis (RA), systemic lupus erythematosus, acquired immunodeficiency syndrome, and chronic renal failure are associated with high Lp(a) levels. In cases of RA, high Lp(a) levels are reversed by interleukin-6 receptor (IL-6R) blockade by tocilizumab, suggesting a potential role for IL-6 in regulating Lp(a) plasma levels. Elevated levels of IL-6 and IL-6R polymorphisms are associated with CVD. Therapies aimed at lowering apo(a) and thereby reducing plasma Lp(a) levels are in clinical trials. Their results will determine if reductions in apo(a) and Lp(a) decrease cardiovascular outcomes. As we enter this new arena of available treatments, there is a need to improve our understanding of mechanisms. This review will focus on the role of Lp(a) in inflammation and CVD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect